Review
Neurosciences
Wolfgang Trapp, Andreas Heid, Susanne Roder, Franziska Wimmer, Goran Hajak
Summary: Cognitive remediation (CR) has proven to be effective in improving cognition and enhancing everyday functional outcomes for individuals with psychiatric disorders. This paper provides practical advice to optimize the effects of CR interventions, including making the interventions fun and motivating, using positively toned emotional stimuli, addressing basic processing deficits, stimulating metacognition and social cognition, and linking tasks to everyday life.
Article
Clinical Neurology
Yu Wang, Li -Peng Bai, Wei Liu, Xiao-Dong Zhu, Xiang -Yang Zhang
Summary: This study found that PD patients with depressive symptoms have lower BDNF levels and poorer cognitive function. BDNF independently contributes to immediate memory, language, and overall cognitive function in patients with depressive symptoms.
PARKINSONISM & RELATED DISORDERS
(2022)
Article
Clinical Neurology
Francesco Benedetti, Mariagrazia Palladini, Greta 'Orsi, Roberto Furlan, Fabio Ciceri, Patrizia Rovere-Querini, Mario Gennaro Mazza, The COVID- BioB Outpatient Clinic group Study
Summary: This study found that COVID-19 survivors have negative thinking styles associated with depressive psychopathology. These survivors experienced negative emotions and affects, hindering their recovery. This cognitive vulnerability has been observed in medical conditions associated with depression, but never explored in post-COVID depression. The findings suggest that the severity of depression is related to dimensions of negative thinking styles, which is important for the treatment of depressed COVID-19 survivors.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Psychiatry
Anna Baumeister, Anja S. Goritz, Charles Benoy, Lena Jelinek, Steffen Moritz
Summary: Evidence is accumulating regarding the persistent psychiatric and neurocognitive effects of COVID-19. A study compared baseline data from 2015 and follow-up data from 2021 of 428 participants to examine long COVID symptoms. Participants with COVID-19 reported more subjective neurocognitive complaints in the follow-up, but this did not correspond to test performance. They also reported greater depressive symptoms compared to the no-COVID group. However, these complaints should be considered in the context of baseline data, as they were present even before COVID infection. Therefore, premorbid performance and psychological factors should be taken into account when discussing long COVID.
PSYCHIATRY RESEARCH
(2022)
Article
Psychiatry
Rianne van Hal, Dirk Geurts, Philip van Eijndhoven, Joosje Kist, Rose M. Collard, Indira Tendolkar, Janna N. Vrijsen
Summary: This study aimed to differentiate participants diagnosed with MDD, ADHD, comorbid MDD + ADHD, and healthy controls using common symptom measures and cognitive dysfunction. The findings showed that all patient groups exhibited clinically relevant levels of ADHD symptomatology, executive dysfunction, and diminished cognitive performances in the domain of attention. Discriminant function analysis based on self-reported symptoms of MDD, ADHD, and executive dysfunction correctly classified all healthy controls and patients diagnosed with ADHD or MDD to a relatively good extent.
JOURNAL OF PSYCHIATRIC RESEARCH
(2023)
Article
Behavioral Sciences
Philippe Voruz, Ioana Medeleine Constantin, Julie Anne Peron
Summary: The longitudinal trajectories of cognitive-neuropsychiatric symptoms in Parkinson's disease vary depending on the motor symptom asymmetry at disease onset. Further investigation is needed to explore the relationship with biomarkers.
Article
Clinical Neurology
Johanna Philipson, Patric Blomstedt, Anna Fredricks, Marwan Hariz, Rasmus Stenmark Persson, Marjan Jahanshahi
Summary: Studies indicate that bilateral cZi DBS for PD patients generally do not have adverse cognitive effects, and cognitive function remains stable in both short and long term, although there may be declines in attention and self-reported executive function.
JOURNAL OF NEUROSURGERY
(2021)
Review
Clinical Neurology
Dominik Kriesche, Christian F. J. Woll, Nadja Tschentscher, Rolf R. Engel, Susanne Karch
Summary: This study aimed to update current assumptions and investigate the extent of cognitive impairment in major depressive disorder. The findings showed significant impairment in processing speed, learning, and memory in the acute phase, and residual deficits in attention, learning and memory, and working memory in remission. There was a positive correlation between the number of episodes and cognitive deficits, as well as depression severity and cognitive deficits. The results supported the global deficit hypothesis and were consistent with prior meta-analyses and reviews.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
(2023)
Article
Clinical Neurology
Niall McIntyre Broomfield, Robert West, Mark Barber, Terence J. Quinn, David Gillespie, Matthew Walters, Allan House
Summary: This study assessed the prevalence and course of poststroke emotionalism (PSE) in stroke patients and found that PSE is associated with symptoms of anxiety and event-related distress.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Clinical Neurology
Brendan McLaren, Sophie C. Andrews, Yifat Glikmann-Johnston, Emily-Clare Mercieca, Nicholas W. G. Murray, Clement Loy, Mark A. Bellgrove, Julie C. Stout
Summary: Smartphone-based cognitive assessment through HD-Mobile demonstrates robust known-groups, test-retest reliability, concurrent validity, and sensitivity in HD patients. The study highlights the feasibility and utility of HD-Mobile for convenient, frequent assessment of HD samples without the need for in-person assessment.
JOURNAL OF NEUROLOGY
(2021)
Review
Medicine, General & Internal
Wenjie Zhang, Bin Deng, Fen Xie, Hang Zhou, Ji-Feng Guo, Hong Jiang, Amy Sim, Beisha Tang, Qing Wang
Summary: This article systematically reviewed randomized controlled trials (RCTs) on repetitive transcranial magnetic stimulation (rTMS) in patients with Parkinson's disease (PD), evaluating the efficacy of rTMS on motor and non-motor function in PD patients. The results showed that rTMS had a significant effect on improving motor symptoms and potentially alleviating depressive symptoms in PD.
Review
Clinical Neurology
Harry Costello, Alex J. Berry, Suzanne Reeves, Rimona S. Weil, Eileen M. Joyce, Robert Howard, Jonathan P. Roiser
Summary: Reward processing impairment in Parkinson's disease varies according to dopamine medication state and subcomponents, suggesting a potential treatment target and mechanism underlying associated neuropsychiatric syndromes. Impulse control disorder is the only neuropsychiatric syndrome with enough studies for meta-analysis, showing no significant impairment compared to non-ICD patients.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Clinical Neurology
Seong Ho Jeong, Hyun-Jae Jeong, Mun Kyung Sunwoo, Sung Soo Ahn, Seung-Koo Lee, Phil Hyu Lee, Yun Joong Kim, Young H. Sohn, Chae Jung Park, Seok Jong Chung
Summary: The volume of the choroid plexus (CP) is associated with cognitive decline and dementia conversion risk in patients with Parkinson disease (PD). A larger CP volume is correlated with lower baseline frontal/executive function scores and higher risk of dementia conversion. The effect of CP volume on dementia conversion is completely mediated by frontal/executive function.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Psychology, Multidisciplinary
Jennifer A. Foley, Lisa Cipolotti
Summary: Apathy in Parkinson's disease often coexists with depression and anxiety, with pure apathy being rare. Patients with mood disorders perform worse in non-verbal intellectual functioning, while those with apathy do not show additional cognitive losses. This suggests that apathy in PD may be primarily an epiphenomenon of mood disorder.
FRONTIERS IN PSYCHOLOGY
(2021)
Article
Clinical Neurology
Saul Martinez-Horta, Jesus Perez-Perez, Javier Oltra-Cucarella, Frederic Sampedro, Andrea Horta-Barba, Arnau Puig-Davi, Javier Pagonabarraga, Jaime Kulisevsky
Summary: There are different types of cognitive decline progression in patients with Huntington's disease, namely a slow progression group and an aggressive progression group. The aggressive group shows a more pronounced loss of functionality and a marked deterioration in motor and psychiatric symptoms.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Daniel Weintraub, Marijan Posavi, Pierre Fontanillas, Thomas F. Tropea, Eugenia Mamikonyan, Eunran Suh, John Q. Trojanowski, Paul Cannon, Vivianna M. Van Deerlin, Alice S. Chen-Plotkin
Summary: In this study, a clinico-genetic predictor called ICD-RS was developed to identify the risk of impulse control disorder (ICD) in Parkinson's disease (PD) patients. The ICD-RS demonstrated a high accuracy in predicting ICD risk and can be used to guide pharmacogenetic approaches to PD medication selection.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2022)
Article
Clinical Neurology
Daniel Johannes van Wamelen, Silvia Rota, Anette Schrag, Alexandra Rizos, Pablo Martinez-Martin, Daniel Weintraub, Kallol Ray Chaudhuri
Summary: This study examines non-motor fluctuations in Parkinson's disease patients, finding that the prevalence of NMF increases with disease duration in a pattern different from motor fluctuations. Additionally, NMF can occur in Parkinson's disease patients without dyskinesia, and the severity of NMF increases most during the 2-5 years after diagnosis.
MOVEMENT DISORDERS CLINICAL PRACTICE
(2022)
Article
Clinical Neurology
David G. Coughlin, Annie Hiniker, Claire Peterson, Yongya Kim, Sanaz Arezoumandan, Lucia Giannini, Donald Pizzo, Daniel Weintraub, Andrew Siderowf, Irene Litvan, Robert A. Rissman, Douglas Galasko, Lawrence Hansen, John Q. Trojanowski, Edward Lee, Murray Grossman, David Irwin
Summary: This study used digital image analysis techniques to evaluate the distribution of tau pathology in different diseases and found that AD and LBD+tau had the highest tau burden in the superior temporal cortex. In addition, 4R-tauopathies had relatively higher white matter tau burden and there was a positive correlation between grey and white matter tau.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
(2022)
Article
Clinical Neurology
Thomas F. Tropea, Teresa Waligorska, Sharon X. Xie, Ilya M. Nasrallah, Katheryn A. Q. Cousins, John Q. Trojanowski, Murray Grossman, David J. Irwin, Daniel Weintraub, Edward B. Lee, David A. Wolk, Alice S. Chen-Plotkin, Leslie M. Shaw
Summary: The objective of this study was to determine if plasma tau phosphorylated at threonine 181 (p-tau181) can distinguish Alzheimer's disease (AD) from normal cognition (NC) in adults, predict cognitive and functional decline, and validate findings in an external cohort. The results showed that plasma p-tau181 can accurately differentiate AD pathology from NC, and higher levels of p-tau181 are associated with faster cognitive and functional decline.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2023)
Article
Clinical Neurology
John L. Robinson, Sharon X. Xie, Daniel R. Baer, EunRan Suh, Vivianna M. Van Deerlin, Nicholas J. Loh, David J. Irwin, Corey T. McMillan, David A. Wolk, Alice Chen-Plotkin, Daniel Weintraub, Theresa Schuck, Virginia M. Y. Lee, John Q. Trojanowski, Edward B. Lee
Summary: In this retrospective study, the incidence of 10 pathologies in neurodegenerative disease (ND) and normal aging was examined, with up to seven pathologies observed concurrently resulting in 161 different combinations. The presence of multiple additive pathologies was associated with factors such as longer disease duration, clinical dementia, older age, and APOE e4 status.
Article
Clinical Neurology
Danielle S. Abraham, Thanh Phuong Pham Nguyen, Leah J. Blank, Dylan Thibault, Shelly L. Gray, Sean Hennessy, Charles E. Leonard, Daniel Weintraub, Allison W. Willis
Summary: This study examined the differential prescribing patterns between new and established treatments for common neurological conditions. Using data from a national sample of US commercially insured adults from 2005-2019, the study compared new users of recently approved medications for three conditions: diabetic peripheral neuropathy, Parkinson disease psychosis, and epilepsy. The results showed that newer medications were more frequently prescribed to individuals with prior treatment, suggesting potential bias in comparative effectiveness and safety studies. The study emphasizes the importance of reporting propensity score non-overlap in comparative studies involving newer medications and suggests methodological approaches to address channeling bias.
Article
Clinical Neurology
Katheryn A. Q. Cousins, David J. Irwin, Alice Chen-Plotkin, Leslie M. Shaw, Sanaz Arezoumandan, Edward B. Lee, David A. Wolk, Daniel Weintraub, Meredith Spindler, Andres Deik, Murray Grossman, Thomas F. Tropea
Summary: This study found that plasma GFAP may be sensitive to concomitant AD pathology in LBSD, especially accumulation of beta-amyloid plaques.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2023)
Article
Neurosciences
Kalpana M. Merchant, Tanya Simuni, Janel Fedler, Chelsea Caspell-Garcia, Michael Brumm, Kelly N. H. Nudelman, Elizabeth Tengstrandt, Frank Hsieh, Roy N. Alcalay, Christopher Coffey, Lana Chahine, Tatiana Foroud, Andrew Singleton, Daniel Weintraub, Samantha Hutten, Todd Sherer, Brit Mollenhauer, Andrew Siderowf, Caroline Tanner, Ken Marek
Summary: We quantified concentrations of three isoforms of BMP in different cohorts of Parkinson's disease patients and found that LRRK2 and GBA1 gene mutations were associated with elevated BMP levels. However, BMP is not a prognostic or disease progression biomarker.
NPJ PARKINSONS DISEASE
(2023)
Article
Clinical Neurology
Daniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, Chelsea Caspell-Garcia, Cornelis Blauwendraat, Ethan G. Brown, Lana M. Chahine, Christopher S. Coffey, Roseanne D. Dobkin, Tatiana Foroud, Doug Galasko, Karl Kieburtz, Kenneth Marek, Kalpana Merchant, Brit Mollenhauer, Kathleen L. Poston, Tanya Simuni, Andrew Siderowf, Andrew Singleton, John Seibyl, Caroline M. Tanner
Summary: This study used data from a multi-site, international, prospective cohort study to investigate the impact of dopamine system-related biomarkers on cognitive impairment in Parkinson's disease. The results showed that alterations in the dopamine system were associated with the development of cognitive impairment in Parkinson's disease. If confirmed causative, these findings suggest that the dopamine system is instrumental to cognitive health status throughout the disease course.
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Article
Clinical Neurology
Daniel Weintraub
MOVEMENT DISORDERS
(2023)
Article
Clinical Neurology
Hubert H. Fernandez, Daniel Weintraub, Eric Macklin, Irene Litvan, Michael A. Schwarzschild, Jamie Eberling, Aleksandar Videnovic, Christopher J. Kenney
Summary: In patients with Parkinson disease dementia (PDD), SYN120 did not improve cognition significantly but showed potential benefits in cognitive activities of daily living and apathy.
PARKINSONISM & RELATED DISORDERS
(2023)
Article
Clinical Neurology
Thanh Phuong Pham Nguyen, Shelly L. Gray, Craig W. Newcomb, Qing Liu, Ali G. Hamedani, Daniel Weintraub, Sean Hennessy, Allison W. Willis
Summary: This study found that there were no significant differences in medication prescriptions between Parkinson disease (PD) patients hospitalized for serious injury and those hospitalized for other reasons, indicating a missed opportunity to deprescribe high-risk medications during care transitions.
PARKINSONISM & RELATED DISORDERS
(2023)
Article
Clinical Neurology
Vindhya Koneru, Alberto J. Espay, Allan J. Cole, Daniel Weintraub, Kathleen Crist, Maria B. Pascual, William G. Ondo
MOVEMENT DISORDERS
(2023)
Article
Clinical Neurology
Daniel Weintraub
MOVEMENT DISORDERS
(2023)
Meeting Abstract
Clinical Neurology
Connie Marras, Lakshmi Arbatti, Amy Amara, Karen Anderson, Claire Bale, Lana Chahine, Shirley Eberly, Abhishek Hosamath, Daniel Kinel, Sneha Mantri, Soania Mathur, David Oakes, Jennifer Purks, Daniel Weintraub, Ira Shoulson
ANNALS OF NEUROLOGY
(2022)